SEC Form 4 · accession 0001144204-16-089643
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillandas T. Thompson
Officer — See Remarks
Period of report
Mar 22, 2016
Accepted (ET)
Mar 22, 2016 · 6:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ADSsF1,F2 | Mar 22, 2016 | P | 10,000 | $11.103 | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.36 | holding | — | — | — | — | Dec 12, 2023 | ADSs | 100,000 | 100,000 | D |
| Stock Option (right to buy)F4 | $16.30 | holding | — | — | — | — | Dec 11, 2024 | ADSs | 95,000 | 95,000 | D |
| Stock Option (right to buy)F5 | $14.35 | holding | — | — | — | — | Dec 10, 2025 | ADSs | 100,000 | 100,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts.
- F210,000 are Restricted ADSs granted under the issuer's "Free Shares" award program on 12/11/2014. All of such 10,000 restricted ADSs will vest and be issued to the reporting person on the fourth anniversary of the grant date, provided that the reporting person continues to be employed by the issuer or an affiliate thereof on that date.
- F3Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date.
- F4Options become exercisable as to 23,750 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- F5Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
Remarks
Sr. VP, General Counsel and Corporate Secretary